In the shadow of Table Mountain, where the fight against HIV/AIDS once heralded a triumph of human resilience, a new storm brews. President Donald Trump’s abrupt freeze on U.S. foreign aid in January 2025 has sent shockwaves through South Africa’s antiretroviral (ARV) programs, threatening to unravel decades of progress. A damning GroundUp investigation uncovers the raw fallout: clinic closures, medicine stockouts, and plummeting testing rates that could unleash a torrent of new infections. As PEPFAR—the U.S.-led lifeline that has saved millions—falters, South Africa grapples with a stark reality: how to plug the gaps before it’s too late.
Since its launch in 2003, PEPFAR has poured over $100 billion into global HIV efforts, with South Africa as a cornerstone. Here, 7.8 million people live with HIV—the world’s highest burden—yet treatment coverage soared to 78% by 2024, slashing AIDS-related deaths by 66% since 2010. But Trump’s executive order, halting all foreign aid for a 90-day review to align with “American interests,” upended this fragile equilibrium. USAID contracts, worth R5.2 billion in South Africa alone, were slashed by 89%, triggering immediate chaos. This sudden stop-work order not only paused new grants but also froze existing ones, leaving programs in limbo and forcing rapid reallocations that few could manage.
The Immediate Hammer Blow: Clinics Shut, Patients Adrift
The cuts hit like a thunderclap. In Johannesburg’s bustling clinics, USAID-funded staff—nearly half of all lay counselors and data capturers—were laid off overnight. One major HIV facility lost eight counselors, eight data capturers, a clinical manager, and a medical officer in February 2025. HIV testing in the district plunged 8.5%, diagnoses cratered 31%, and new treatment starts nosedived 30% in the first quarter compared to 2024. These disruptions echoed across urban and rural divides, where understaffed facilities struggled to absorb the surge in patients seeking alternatives.
Across the country, ARV stockouts emerged as the cruelest symptom. Patients like Gugu, a 54-year-old former sex worker in Johannesburg, once collected nine-month supplies from USAID-backed drop-in centers tailored for high-risk groups. Now, with those centers shuttered, she faces interminable queues at public hospitals—arriving at dawn, waiting all day, only to encounter dismissive staff ill-equipped for her needs. “Time is money for sex workers,” she says, her voice laced with dread. “Many will just stop treatment, and that means death.” Gugu’s story is far from unique; countless others in similar positions report skipping doses due to access barriers, risking not only their health but also the spread of drug-resistant strains that could complicate future treatments nationwide.
National data paints a grimmer picture. Viral load testing, crucial for monitoring treatment efficacy, dropped up to 21% among key populations by May 2025, per the National Health Laboratory Service. In high-burden districts, where U.S. funding underpinned 50% of counseling and 80% of data management, service disruptions rippled outward. Mobile clinics vanished, outreach to sex workers and LGBTQIA+ communities evaporated, and PrEP uptake—vital for prevention—tumbled, with only 19% of sex workers accessing it through government facilities versus 40% via PEPFAR programs. The loss of these targeted interventions has particularly devastated vulnerable groups, widening inequalities in care and prevention that South Africa has fought hard to narrow over the past decade.
Projections of Peril: A Modeling Nightmare Unfolds
GroundUp’s probe, drawing on a University of Cape Town and Witwatersrand study commissioned by the National Health Department, models a dystopian horizon. If PEPFAR funding vanishes entirely, South Africa could see 150,000 to 295,000 extra HIV infections by 2028, ballooning to hundreds of thousands more by 2045. That’s alongside 56,000 to 65,000 additional deaths in the near term, escalating to 500,000–700,000 over two decades. These projections account for cascading effects, including reduced viral suppression rates that could fuel community transmission and strain already overburdened healthcare systems.
The methodology is rigorous: using Thembisa baseline data (78% ARV coverage in 2024), researchers simulated coverage dips—from 81% in 2026 to as low as 59% in worst-case scenarios. Prevention craters too: a 55% PrEP reduction for female sex workers by 2026, closure of drop-in centers, and loss of 2,000 lay counselors for testing. Echoing this, a UNAIDS report warns of six million global new infections and four million AIDS deaths by 2029 without intervention, with sub-Saharan Africa—where half of 2024’s cases occurred—bearing the brunt. The report highlights how the funding pause has already interrupted supply chains for essential medicines, projecting a 14% drop in treatment initiations across the region in the first half of 2025 alone.
These aren’t abstract figures. In Mozambique, a PEPFAR bellwether, treatment starts fell 14% from February to May 2025, viral suppression dropped 33% in adults, and interruptions surged 39%. South Africa’s trajectory mirrors this, with experts like Professor Linda-Gail Bekker of the Desmond Tutu HIV Centre decrying the “disastrous” halt. “HIV treatment doesn’t stand still,” she warns. “PrEP and quality care must keep flowing.” Bekker’s concerns are echoed by international bodies, which note that the freeze has halted clinical trials and research initiatives critical for long-term solutions, such as next-generation vaccines and long-acting injectables.
Beyond the Numbers: Stories of Survival and Stigma
Behind the stats lie human sagas of fragility. Gugu’s NGO once shielded pregnant sex workers from mother-to-child transmission, a PEPFAR success story now imperiled. Without discreet services, stigma drives defaults: files in public hospitals expose sensitive details, and long waits exacerbate poverty’s grind. In rural KwaZulu-Natal, where HIV prevalence exceeds 25%, mothers like Thandi face even steeper challenges, traveling hours to reach facilities only to find empty shelves or untrained staff unable to provide the counseling that once empowered them to protect their children.
Professor Lynn Morris of Wits University laments a “real success story” unraveling. “We’re seeing spikes in infections, TB, and lost research on vaccines and cures,” she says, noting halted trials for drugs like Lenacapavir that promised near-total protection. Professor Abdullah Ely adds that shifting African-led studies to Europe or the U.S. robs the continent of agency, delaying progress by years. The ripple effects extend to co-morbidities; untreated HIV weakens immune systems, fueling tuberculosis outbreaks and straining resources in a country already grappling with high rates of both diseases.
Yet resilience flickers. Legal challenges briefly restored some funds, but damage lingers—medicines stranded in warehouses, programs in limbo. GroundUp’s lens reveals not just loss, but a clarion call: South Africa’s 17% PEPFAR dependency belies its outsized role in efficient, targeted delivery. Government clinics stock 96% of PrEP needs, but without NGO outreach, high-risk uptake will plummet. Community health workers, often the unsung heroes of the response, are stepping up with volunteer efforts, but without sustained funding, their impact remains limited.
Government Gambit: Can Local Funds Stem the Tide?
The National Health Department insists the HIV response remains robust, with U.S. aid covering just 17% of spending—R7.5 billion annually. Spokesperson Foster Mohale urges continuity at public facilities, but admits PrEP rollout for key populations is a “work in progress.” Finance Minister Enoch Godongwana pledged partial aid in his budget speech, yet no specifics emerged on the R13–30 billion needed through 2028 to avert catastrophe. Efforts to reallocate domestic budgets are underway, including tax incentives for private sector contributions and partnerships with local philanthropists, but scaling these quickly enough to fill the void poses a monumental challenge.
Professor Francois Venter stresses outreach’s irreplaceability: “Directing sex workers to clinics won’t work—stigma and access barriers persist.” Dr. Yogan Pillay advocates national evaluations of delivery models, trimming NGO inefficiencies for sustainable scaling. International lifelines offer glimmers: R100 million each from the Bill & Melinda Gates Foundation and Wellcome Trust, plus R400 million from government over three years. But experts like Bekker hammer home self-reliance: “National governments must step up—sudden donor stops are disastrous, but preparation is key.” Drawing lessons from past crises, such as the 2008 financial downturn, South Africa is exploring innovative financing like HIV bonds and public-private consortia to diversify funding streams.
In Malawi, where PEPFAR funds two-thirds of HIV efforts, the National AIDS Commission echoes this, urging accelerated domestic strategies to meet 2030 goals. For South Africa, the path forward demands bold reallocations—bolstering lay counselors, reviving mobile units, and fortifying research hubs like the 39 U.S.-backed sites now at risk. Integrating HIV services with universal health coverage initiatives could provide a buffer, ensuring that prevention and treatment remain priorities even as external support wanes.
A Call to Reclaim the Momentum
South Africa’s HIV odyssey—from apocalypse in the 1990s to near-victory—hangs by a thread. Trump’s aid withdrawal, while geopolitically motivated, exposes the perils of overreliance on foreign benefactors. Yet in this crucible lies opportunity: to forge a homegrown fortress against the virus. By investing in local innovation, from community-led testing to AI-driven supply chain management, the nation can turn vulnerability into strength.
The GroundUp investigation isn’t mere alarm—it’s a blueprint. By bridging funding chasms with targeted investments, South Africa can safeguard its 5.9 million on ARVs and prevent the unthinkable resurgence. As Bekker reminds us, “We know self-reliance is essential.” The question isn’t if South Africa can endure, but how swiftly it acts to ensure no life is lost to yesterday’s generosity or tomorrow’s neglect. With global eyes watching, this moment could redefine not just one country’s response, but the blueprint for equitable health security worldwide.